A Phase 3 registrational program for PN-943 in moderate-to-severe ulcerative colitis
Latest Information Update: 26 Apr 2022
At a glance
- Drugs PN 10943A (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Protagonist Therapeutics
Most Recent Events
- 26 Apr 2022 New trial record
- 25 Apr 2022 According to a Protagonist Therapeutics media release, Plans for the Phase 3 registrational study are underway